This study is a prospective, phase II clinical trial with the primary objective of assessing the effectiveness of demethylating agents combined with venetoclax in the prevention of recurrence after allogeneic hematopoietic stem cell transplantation (allo-HSCT) of high risk T-lymphoblastic lymphoma/leukemia (T-LBL/ALL) patients.
1.14-55 years old, male,or female.
2.Patients with allo-HSCT due to T-LBL/ALL, the donor type is not limited.
3.ECOG score is 0-2 points.
4.Blood routine: ANC ≥ 1.0 × 109/L, PLT ≥ 50 × 109/L.
1.Central involvement during any course of the disease.
2.Patients who have not achieved complete remission before transplantation.
3.Identify those with available targeted drugs.
4.For those who are resistant to BCL-2 inhibitors before transplantation, if the disease progresses during the application process, or if 3-4 courses of induction therapy containing BCL2 inhibitors do not improve.